Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.
about
Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation.Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
P2860
Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Neoadjuvant Treatment of High- ...... rior to Radical Prostatectomy.
@en
type
label
Neoadjuvant Treatment of High- ...... rior to Radical Prostatectomy.
@en
prefLabel
Neoadjuvant Treatment of High- ...... rior to Radical Prostatectomy.
@en
P2860
P1476
Neoadjuvant Treatment of High- ...... rior to Radical Prostatectomy.
@en
P2093
Eugene J Pietzak
James A Eastham
P2860
P2888
P356
10.1007/S11934-016-0592-4
P577
2016-05-01T00:00:00Z
P6179
1051403128